A pilot comparison of remote versus in-clinic digital cognitive assessments for older adults in primary care settings.

Louisa Thompson, Ph.D.,[1,2] Charles Eaton, M.D., M.S.,[3,7] Sarah Prieto, Ph.D.,[1,2] Molly Lawrence, B.S.,[1] Stephanie Czech, Ph.D.,[3] Jennifer Rosenbaum, M.D.,[3] David Anthony, M.D.,[3] Rabin Chandran, M.D.,[3] Lauren Kelly, P.A.-C.,[3] Ivy Ngo, M.D.,[3] Arnold Goldberg, M.D.,[3] Caitlin Gillooly, M.D.,[3] Nelson Roque, Ph.D.,[4] Hailey Andrews, B.S.,[4] A. Rani Elwy, Ph.D.,[2,8] Richard N. Jones, Sc.D.,[1] Dorene M. Rentz, Psy.D.[5,6]

[1]Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University
[2]Memory & Aging Program, Butler Hospital
[3]Department of Family Medicine, Alpert Medical School of Brown University
[4]The Pennsylvania State University, College of Health and Human Development
[5]Department of Neurology, Massachusetts General Hospital, Harvard Medical School
[6]Center for Alzheimer Research & Treatment, Brigham and Women's Hospital, Harvard Medical School
[7]Department of Epidemiology, School of Public Health, Brown University [8]Center for Healthcare Optimization and Implementation Research, VA Bedford Healthcare System

Correspondence concerning this article should be addressed to Louisa Thompson, Department of Psychiatry, Alpert Medical School, Brown University, Providence, RI. Address: 345 Blackstone Blvd., Providence, RI 02906. Phone: 401-455-6402. E-mail: louisa_thompson@brown.edu

Abstract:
BACKGROUND: Timely identification of mild cognitive impairment (MCI) is critical for maximizing early intervention opportunities in older adults at risk for dementia. This study evaluated the feasibility, acceptability, and validity of novel digital cognitive tests in primary care.
METHODS: In a 16-month, two-phase pilot study across three clinics, 51 older adults completed digital cognitive assessments remotely on personal devices followed by supervised tablet-based cognitive screening in-clinic and the Montreal Cognitive Assessment (MoCA). Surveys and interviews assessed patient and provider acceptability. Digital test completion rates were examined to assess feasibility.
RESULTS: Completion rates ranged from 60% - 76% for the at-home assessments and 81.8% for in-clinic testing. Participants generally preferred at-home testing. Providers found in-clinic testing acceptable but identified barriers related to device access and EMR integration. All but one digital test showed moderate correlations with the MoCA.
CONCLUSION: Digital cognitive screening—whether remote or in-clinic—shows promise for primary care implementation.

Keywords: Primary Care, Cognitive Screening, Alzheimer's disease, Mild Cognitive Impairment, Digital Assessment, Early Detection.

Background:

The development of new and improving disease-modifying treatments and lifestyle interventions for individuals in the early stages of Alzheimer's disease (AD) makes it increasingly important to identify individuals at risk for cognitive decline as early as possible. Yet, recent estimates from U.S. CMS data have revealed substantial discrepancies between the rates of diagnosis and the actual prevalences of mild cognitive impairment (MCI) and AD among older adults seen in primary care and other general medical settings.[1,2] These discrepancies are particularly pronounced for MCI, with a projected 92% of cases undiagnosed among Medicare beneficiaries, and even higher rates among Black and Hispanic/Latino older adults.[2] Missed and/or delayed diagnoses not only heighten the risk of disease progression but also limit opportunities for patients to adopt beneficial lifestyle changes or access newly available treatments.

While advances in plasma AD biomarkers have led to the rapid development of commercially available blood tests to assist in the diagnosis of AD, recent guidelines from the Alzheimer's Association and the Global CEO Initiative state that these plasma biomarkers should only be used in the context of cognitive decline.[3,4] Unfortunately, existing cognitive screening tools, with the exception of the Montreal Cognitive Assessment (MoCA), are woefully insensitive for accurately detecting MCI, particularly in diverse older adults in primary care.[5] With an estimated 88% of U.S. older adults using the internet regularly, now is the time to investigate alternative digital approaches to cognitive screening.[6] Several digital cognitive assessment tools have been developed and shown to be feasible, valid and highly reliable in cognitively healthy older adults, but most of these tools have not been validated for use in primary care.[7,8] Moreover, given time constraints faced by primary care practitioners, there is growing need to determine whether digital assessments could be self-administered remotely (i.e., at home) by older adults to initiate diagnosis or supplement ongoing cognitive monitoring. This is particularly relevant now that new FDA-approved Alzheimer's disease-modifying therapies and FDA-approved blood tests for AD biomarkers are available. As such, developing new protocols and best practice guidelines for digital cognitive testing in routine preventative care, such as Medicare Annual Wellness Visits (AWV) is a priority.

We sought to identify feasible, acceptable, and valid approaches for integrating digital cognitive screening tools in primary care settings. We designed and conducted the present pilot study to compare two approaches: self-administered, digital assessment at home and supervised digital assessment in the clinic. Our objectives were threefold. First, to determine if remote and in-clinic digital tests show preliminary feasibility determined by test completion rates. Second, to use a mixed methods approach to characterize the acceptability of digital tests among patients and providers. And third, to conduct a preliminary comparison of remote versus in-clinic digital assessment for identifying impaired versus unimpaired older adults using the Montreal Cognitive Assessment (MoCA) as a reference standard paper-based cognitive test.

Methods:

Study Design and Description of Clinics:
Data were collected during a 16-month, iterative design, context-informed pilot feasibility study with two phases for testing an original and an adjusted protocol, respectively (hereafter referred to as Protocol 1 and Protocol 2 – see Figure 1). Planned adjustments from Protocol 1 to Protocol 2 included piloting different remote assessments and assessing the feasibility of an entirely clinic-based protocol prior to introducing the additional MAP study visit. Five primary care providers (PCPs) across three clinics aided in protocol 1 development through focus groups. Four of these providers (80%) continued to collaborate in data collection for the pilot study and four additional providers were also recruited over the course of the study. Clinic A was a hospital-affiliated community clinic serving an underserved population, with an integrated behavioral health team and two participating PCPs. Clinic B was a Federally Qualified Community Health Center with three PCPs participating in the study. Clinic C was a hospital-affiliated general family medicine clinic with three participating PCPs.

Recruitment:
We utilized a multipronged approach for recruiting patient participants to maximize insights for future research. Passive methods included mailings, MyChart messages (clinic A and clinic C only), and waiting room flyers. Using electronic medical record (EMR) searches, we identified potential participants (age range of 55-85, no dementia diagnosis) from each participating PCP's panel and mailed them a letter advertising the study. Direct recruitment strategies included phone calls to MyChart users with account preferences indicating willingness to be contacted for research, as well as phone calls to potential participants identified by the PCP.

Screening and enrollment:
Screening and consent were conducted over the phone. Eligibility criteria required participants to be fluent in English for Protocol 1, and in either English or Spanish for Protocol 2. Exclusion criteria were existing dementia diagnosis or other neurological disease, a score of <13 on the telephone version of the MoCA,[9] less than four years of education, current substance use disorder, acute or unstable psychiatric illness, and motor or sensory conditions that would compromise cognitive test validity based on self-report during screening. Potential participants provided verbal consent to complete telephone screening and enrolled in the study via RED-Cap-based eConsent form. The project received approval from the Butler Hospital Institutional Review Board, and all participants provided informed consent. The research was completed in accordance with the Helsinki Declaration. Compensation included $20 for completing remote study activities and $40 for completing the study visit at the Butler Hospital Memory and Aging Program (MAP) for Protocol 2.

Digital cognitive assessment protocols:

Figure 1. Protocol schedules for each phase of piloting.



Note. Planned adjustments from Protocol 1 to Protocol 2 included piloting different remote assessments and assessing the feasibility of an entirely clinic-based protocol prior to introducing the additional MAP study visit. PCP = Primary Care Provider, t-MoCA and MoCA = Telephone version and standard version, respectively, of the Montreal Cognitive Screening Assessment, BOCA = Boston Cognitive Assessment, DCR = Digital Clock and Recall test, CANTAB PAL = Cambridge Neuropsychological Test Automated Battery Paired Associates Learning test, M2C2 = Mobile Monitoring of Cognitive Change.

<u>Online assessment with the BOCA (protocol 1)</u>: Remote assessment was conducted via smartphone, personal computer, or tablet at two timepoints, between 1-4 weeks prior to the participant's AWV or routine follow-up, and again, within one day of the appointment. Participants were emailed a link to complete the test and received reminder emails and/or phone calls as needed. We used the Boston Cognitive Assessment (BOCA), a 10-minute online test of global cognition assessing orientation, immediate and delayed recall, executive function, visuospatial ability, attention, and language.[10] Alternate forms are given for repeat assessment. Additional test characteristics and psychometrics have been published previously.[10] The BOCA has been strongly correlated with the MoCA in both memory clinic patients and healthy controls and has demonstrated sensitivity to cerebral amyloid status in individuals with MCI.[10-12]

<u>Smartphone assessment with CANTAB and M2C2 (protocol 2):</u>
Participants were emailed web links to complete a single 10-minute memory test (Paired Associates Learning; see below) followed by 5 consecutive days of brief Mobile Monitoring of Cognitive Change (M2C2) cognitive assessments on their own smartphone.

Participant progress was monitored, and reminder emails and/or phone calls were made as needed.

We used the 10-minute Paired Associates Learning (PAL) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB^{R}, Cambridge Cognition), a validated visual learning and memory test, which has recently been adapted for smartphone administration.[13,14] Previous studies have shown that the PAL is sensitive to AD biomarkers, distinguishes between MCI and normal cognition, and predicts disease progression.[15-17]

Participants completed high frequency assessment (HFA) of cognitive performance from the M2C2 platform over 5 days, delivered via WebView in the Metricwire Catalyst mobile app. M2C2 tasks included measures of visuospatial working memory, processing speed, and episodic memory, which have been previously validated and described.[18,19] Studies have shown that HFA approaches using M2C2 and similar platforms are highly reliable, distinguish accurately between MCI and normal cognition, and are sensitive to AD biomarkers.[20-22] Participants completed 4-minute sessions consisting of the three tasks and survey questions in the morning and evening. Participants also completed a 1-minute session with just the processing speed task in the afternoon. Push notifications from the app were set as reminders.

<u>Assessment in clinic (Protocols 1 and 2)</u>:
Following remote testing, in-clinic testing was completed via tablet during the participant's appointment with their PCP. All PCPs opted to administer the assessment themselves, though an option was also given for a medical assistant to administer it when rooming the patient. We used the Linus Health Digital Clock and Recall (DCR^{TM}), a 3-5-minute assessment designed for in-clinic self-administration supervised by a healthcare professional. The test consists of 3-word learning, clock drawing task (drawn with stylus) and 3-word recall. A cloud-based machine learning-derived scoring algorithm calculates a total score out of 5 points as well as sub-scores. A report is automatically generated with cutoffs for impaired, intermediate, and unimpaired performances and recommendations for next steps. The DCR^{TM} scoring algorithm has previously been deployed in primary care settings with good accuracy for distinguishing between individuals with and without cognitive impairment.[23-25]

Cognitive health consultation:
Participants also completed a brief cognitive health consultation, which was conducted either immediately following their PCP appointment or scheduled as a follow-up conducted within a 1-month window. During protocol 1, a study coordinator conducted the consultations at two of the three clinics, and at the third an integrated behavioral health team was trained to complete the consultations. During protocol 2, consultations were done onsite at the MAP. Consultation included Montreal Cognitive Assessment (MoCA) to provide a reference standard for validation of the digital assessments. MoCA results were reviewed with each participant, and they were given educational resources and referral options as needed. During protocol 1, the MoCA was scanned into the

participant's medical record. In both pilot phases, impaired MoCA scores were communicated to the PCP and referral to our MAP clinic was offered.

Survey & Interview:
Participants gave feedback on their experience completing the digital tasks via a 5-10-minute REDCap survey developed to assess acceptability constructs including test preference, difficulty, and usability, as well as comfort and stress associated remote versus in-clinic testing. Provider feedback was obtained in the form of 20-30-minute semi-structured interviews conducted via Zoom. A minimum of 5 DCR administrations was a prerequisite for providers to complete the provider interview. Providers were asked to describe their experience using the DCR assessment and asked to give any feedback on how to improve the in-clinic protocol.

Analysis:
Analyses were conducted to examine whether there were differences in education, race, or employment status between individuals who were enrolled in the study (n = 51) and those who were not enrolled (n = 40). A Wilcoxon rank-sum test was used for the continuous variable (education) and chi-squared test was used for categorical variables (race and employment status). We set a benchmark completion rate of 80% to assess the feasibility of the remote and in-clinic digital cognitive assessment protocols. A brief exit survey was used to assess acceptability among patient participants, while provider feedback was obtained via semi-structured interview. Test-retest reliability was calculated for the BOCA administered across the two timepoints (1-4 weeks apart) for Protocol 1. Convergent validity was tested using Pearson's and Spearman's correlations between digital assessments and scores from the MoCA. Area under the curve (AUC) analyses were conducted to examine BOCA and DCR accuracy for distinguishing cognitive impairment on the MoCA using a standard cutoff score of 26. During Protocol 1 only, DCR clock drawing performance was used for calculating the clock drawing scores for the MoCA to avoid practice effects.

Results:

Participants:
A total of 91 older adults (Protocol 1 n = 48; Protocol 2 n = 43) were screened for the study. Of these,18 did not meet eligibility criteria. During Protocol 2, seven declined to consent following the screening due to unwillingness to travel for the study visit. Ultimately, 66 participants provided consent; however, 15 (Protocol 1 n = 9; Protocol 2, n = 6) withdrew or were lost to follow-up before completing any study activities. Reasons (when given) for withdrawal included not having enough time (n = 2) or needing to focus on other high priority health conditions (n = 1). Overall attrition rate was 22% and the final enrolled sample size was N = 51, including n = 25 from Protocol 1 and n = 26 from Protocol 2. See Table 1 for sample characteristics.

Results indicated no significant differences between screened and enrolled participants in terms of education (p = 0.08), or race (p = 0.75). There was a significant difference in employment status (χ^2 = 9.04, *p* = .01), such that unemployed individuals were

significantly less likely to be enrolled, while retired individuals were more likely to be enrolled.

Feasibility:

Recruitment: Of approximately 80 PCPs contacted via email, we engaged eight volunteers over the course of the study. Patient recruitment was limited to those individuals in the care of our participating PCPs. As described above, several different methods for patient recruitment were used. Across the eight participating PCPs, 650 mail invitations were sent to patients and yielded a response rate of 2.6% for screening. Additionally, 466 messages were sent in MyChart EMR patient portal, yielding a 3.0% response rate for screening. Waiting room flyers did not yield any screening calls. Direct recruitment methods were more productive, with a 17.5% screening rate from 252 phone calls to MyChart users, and a 35.6% screening rate from 45 direct referrals from PCPs. Providing the option for PCPs to directly refer potential participants to the study was particularly useful for recruitment at clinic B, which did not use MyChart. Providers with a higher percentage of older adult patients tended to have higher rates of patient screening and enrollment. A one-way ANOVA showed no significant differences in recruitment method by participant demographics, except for education ($F(3, 87) = 3.27$, $p = .025$). Post-hoc comparisons did not reach the threshold for significance, but higher education was observed among those recruited through MyChart notifications versus phone calls ($p = .06$) or direct referral ($p = .07$).

Digital assessments protocol 1: The completion rate for BOCA administered at time one (T1), 2-4 weeks in advance of the PCP appointment, was 76%. Six participants were non-compliant with T1 BOCA despite follow-up reminders sent via email. The completion rate for BOCA at time two (T2), at home on the day of the participant's PCP appointment, was 64%. The lower rate reflects uncounted data from six participants who completed the test outside of the 1-day time window as well as three who were non-compliant.

Remote assessment protocol 2: The completion rate for CANTAB was 61.5%. The completion rate for M2C2 was 75%. Overall, reasons for not completing remote assessments included technical difficulties ($n = 6$), time commitment ($n = 6$), and non-compliance ($n =3$).

In-clinic assessment: The completion rate for the PCP-administered DCR at the patient's appointment was 81.8%. Reasons for not completing the DCR included lack of time ($n = 4$), technical issues ($n = 2$), and provider forgetting ($n = 2$). A two-sample z test determined that there was no statistically significant difference in the DCR completion rate relative to the BOCA T1 completion rate, $z = -0.56$, $p = .57$.

Acceptability:

Patient participants: Thirty-six participants completed study feedback surveys across Protocols 1 and 2. The majority (54.3%) of participants preferred completing cognitive testing at home, compared to 22.9% who preferred in-clinic testing, and another 22.8% who said they preferred to do both at-home and in-clinic testing. When asked further about their preference, 69.7% reported feeling more comfortable completing cognitive testing at

home, whereas 30.3% felt more comfortable in the clinic. In-clinic testing with the DCR was rated as more difficult by 56.3% compared to the at-home testing. Regarding ease of use (rated on a scale from 1 to 5, with 5 indicating greater ease), participants reported a high level of usability (Mean = 4.14, SD = 0.93). Only 6 participants (16.7%) found cognitive testing to be stressful.

PCP participants: At the time of the pilot phase completion, 5 of the 8 PCPs had completed 5 or more DCR administrations and were invited to do the feedback interview. The recoding from one interview was lost due to technical difficulties, but interview notes were retained. Overall, four out of five providers gave positive feedback on their use of the DCR and endorsed the tablet assessment technology as easy to use (Sup. Table 1). Main advantages of the DCR were described in several comments noting that the technology worked well, patients were generally comfortable completing it, and the provider appreciated that they could often work on something else while the patient was completing the task. In terms of barriers to use, three providers noted hurdles of finding, charging, and logging into the tablet and assessment platform. Three providers also expressed interest in accessing the report on the tablet, a feature that is available but was not introduced during initial onboarding. Providers were divided in terms of how they felt about the duration of the assessment, with one noting the required time as a downside, while the others said that the test was quick to administer or convenient. Recruitment logistics at Clinic B were identified as a significant area for improvement. Specifically, research staff relied on the EMR system at Clinics A and C for coordinating participant data collection, while clinic B had a different system that the research team could not access, which created challenges with scheduling and providing reminders.

Validity:

Digital Clock and Recall (DCR): Spanning Protocol 1 and 2, DCR total score was positively and moderately correlated with MoCA ($r = .60$, $p < .001$, $n = 36$), as well as the BOCA remote test in Protocol 1 ($r = .55$, $p <.01$, $n = 25$). Participants were classified into impaired and unimpaired groups based on the established MoCA cutoff score of <26.[26] Area under the curve (AUC) analysis indicated a DCR total score AUC of .78 for distinguishing MoCA status (Table 2). The MoCA identified eight individuals as impaired, three of whom were classified as unimpaired on the DCR. In contrast, DCR identified two individuals as impaired and six as borderline who were unimpaired on the MoCA.

Boston Cognitive Assessment (BOCA): BOCA test-retest reliability between the T1 and T2 timepoints was good ($r = .81$, $n = 16$, mean time difference =15.5 days, range 4-33 days). Given the low completion rate for BOCA T2, subsequent analyses collapsed across T1 and T2 to examine only the first instance of BOCA completion for each participant ($n = 25$). BOCA total score was positively and moderately correlated with MoCA total score ($r = .671$, $n = 25$). Mean BOCA score was 27.16, SD = 3.25, while mean MoCA score was 26.4, SD =2.65. AUC analysis indicated a BOCA total score AUC of.78 to distinguish cognitive status (Table 2). A cutoff score for identifying impairment has yet to be established for BOCA. As an exploratory analysis to further examine classification agreement, we applied a percentile-based cutoff to the BOCA matching the percentile rank for the established MoCA cutoff score a score of 25 (23rd percentile). The MoCA

identified six individuals as impaired, three of whom were identified as unimpaired on the BOCA. Likewise, BOCA identified six individuals as impaired, three of whom were identified as unimpaired on the MoCA.

Preliminary data for CANTAB and M2C2: 13 out of 15 participants who completed PAL and M2C2 also had complete MoCA data. PAL performance (total first attempt memory score) was not associated with MoCA total score ($r = .53$, $p = .06$) (Table 2). M2C2 Symbol Search performance was associated with MoCA total score ($r = -.58$, $p < .05$), while Grid Memory performance was not ($r = -.02$, $p > .05$) (Table 2).

Discussion:

Our results show that both remote, at-home, online testing and tablet-based, provider-administered testing in-clinic may be feasible and acceptable approaches to cognitive screening for older adults in primary care, but likely require additional support, resources, and education for providers and patients than what is currently available in many primary care settings.

Completion rate indicators of feasibility for patients completing remote testing and providers completing in-clinic testing were similar overall. Specifically, the best completion rates for remote testing (BOCA T1) and in-clinic testing (DCR) were 76% and 81.8%, respectively. Although only the in-clinic DCR testing completion rate met our initial feasibility benchmark of 80%, the difference in completion rates between BOCA and DCR was not statistically significant. Of our two remote tests in Protocol 2, M2C2 had a better overall completion rate (75%) relative to CANTAB (61.5%), suggesting that the high frequency approach used for M2C2 was quite feasible for older adults. For both protocols, providing reminders and a window of at least one week for participants to complete testing at-home facilitated better completion rates. This suggests that unsupervised cognitive assessments, self-administered at home prior to an AWV (or similar), would likely require support from a designated coordinator and/or EMR and AI tools to assist with setup, reminders, and response tracking to achieve adequate fidelity and sustainability in implementation.

Ease of use and acceptability in the intended context of use are also critical aspects of digital assessment feasibility. From a provider acceptability standpoint, we found that while most of the PCPs in our study felt positive about the digital tool itself, technology usability and workflow integration emerged as critical factors that reduced enthusiasm. Challenges with our protocol, such as the need for a separate login system for the testing app and manual documentation of scores in the patient's EMR were viewed as downsides. It is worth noting that EMR integration for digital cognitive testing, including remote tools, are increasingly in development[27] but currently may be cost prohibitive in many clinical contexts. Additionally, while EMR integration for digital assessments is ideal for ease of implementation and care coordination, it may not be practical or relevant in some settings such as smaller rural clinics and private practices.

From the patient's perspective, completing digital cognitive assessments, both at home and in-clinic, was widely viewed as acceptable. More technical challenges arose for patients completing smartphone-based testing in protocol 2 compared to the browser-based, device-agnostic BOCA used in protocol 1. Specifically, the most common reason for technical difficulties with the CANTAB task involved browser compatibility, while the most common difficulties with M2C2 related to challenges with app setup and login. In sum, our patient acceptability findings suggest that browser-based assessments with broad compatibility and easy access via weblink will likely be the most pragmatic for remote, unsupervised digital assessment in this population. Based on feedback from our PCP participants, such approaches may be more readily adopted by providers if they presented home-based assessment results to providers via EMR integration.

All digital tests that were piloted showed good preliminary validity in our comparisons to the MoCA. Consistent with the literature, we found moderate correlations between overall scores on the digital tests and the MoCA.[25] Encouragingly, our results suggest that an unsupervised, online cognitive test (BOCA) completed at home can perform as well as a supervised, in-clinic cognitive test (DCR) for detecting mild cognitive impairment. This important finding underscores how, with adequate support and accessibility, remote testing prior to an annual appointment could be a good option for busy primary care settings to complete first line screening to detect cognitive decline earlier. Such tools could have immense value for scalable detection of individuals who would benefit from further screening or workup for possible cognitive decline. Such an approach could limit in-person testing to those who are most likely in need, instead of trying to make time for screening during appointments for every older adult patient, which is so often time prohibitive.

This study elucidates effective strategies as well as barriers to consider for designing and conducting embedded cognitive screening implementation studies with minimal facilitation. Strengths of this study include the iterative and phased approach to protocol development and piloting, which allowed us to accommodate several clinics with different EMR systems and providers with varying clinical workflows and available support staff. Interestingly PCPs generally opted to administer the DCR themselves despite the option to train support staff; reasons for this included high support staff burdens and turnover. All participants received feedback on their MoCA performance and educational resources upon completion of the study, thereby providing a baseline for future monitoring and improving brain health awareness, two crucial benefits which should be integral to larger implementation studies. A further strength was the development of a Spanish version of the protocol to increase study accessibility and facilitate measure validation for diverse primary care populations. Although we were unsuccessful in including Spanish-speaking participants in the pilot, this work has paved the way for their successful enrollment in a later stage of the study which is ongoing.

Recruitment posed a major barrier to study startup. Engaging providers proved challenging, and those who ultimately volunteered were all university-affiliated with prior experience in academic training and/or research. It is probable that provider buy-in and in-clinic test completion rates would have been lower had we not engaged providers

already familiar with practice-based research, which again points to the importance of considering remote and unsupervised approaches to testing. We found that the direct referrals of potential participants from PCPs yielded the highest rates of successful screening and enrollment of patients in the study. Passive methods, such as distributing flyers in waiting rooms or by mail, were far less effective. These findings highlight the importance of the provider-patient relationship in facilitating research participation, while also suggesting that cognitive screening tools for clinical use, including remote protocols, may be most effective when they are designed to be provider-initiated.

Our study sample of patients and providers was relatively small and limited geographically, which somewhat restricts the generalizability of our findings. Education level was higher, and the proportion of White participants was higher compared to state averages from census data. The use of the MoCA as the reference standard with a cutoff score of <26 was deemed appropriate for our validity analyses based on the demographics of our sample. However, it is worth noting that different MoCA cutoffs, or a different reference standard altogether, may be more appropriate in clinical samples with a higher proportion of patients from diverse racial/ethnic, educational, or cultural backgrounds.[28,29]

One notable limitation of our protocols was that the order of digital assessments could not be randomized, which may have affected completion rates for the individual tasks. To reduce bias in these calculations we based completion rates for each task out of the total number of participants who were engaged in the study and received the assigned task, not counting people who dropped out or were lost to follow-up before initiating any study assessments.

Although evaluating clinical outcomes was not a focus of this study, the involvement of patients in the study successfully facilitated several referrals for further evaluation in our memory clinic or with a neuropsychologist. Additionally, in some cases cognitive screening identified patients with low or borderline scores with possible medical conditions contributing. In these instances, we were able to bring this to the attention of the patient's PCP and recommend a repeat assessment in one year. Dementia care outcomes will be a focus of later reporting for the next phase of this study.

Conclusion:

Recent national survey data suggest that more than three quarters of adults over the age of 65 use the internet regularly and own a smartphone.[6] While technology is readily accessible, low-cost, and increasingly familiar to many older adults, challenges remain with harnessing digital platforms for cognitive screening, particularly in primary care settings, where there is a great need for more sensitive tools to detect MCI. Digital assessment platforms may provide greater convenience and efficiency for patients and healthcare providers when testing is automated, scored automatically, and integrated with or EMR systems. However, understanding barriers and facilitators to use and thoroughly validating novel digital measures in the context of intended use is critical prior to widespread implementation.[30] The results of this pilot study provide preliminary and comparable support for two digital cognitive tests, one unsupervised at-home test (BOCA)

and one supervised in-clinic test (DCR), as acceptable and valid approaches for identifying older adults with MCI in primary care.

ACKNOWLEDGEMENTS:

This work is supported by grants from the NIA (K23AG080159, PI: Thompson) and Rhode Island Advance-CTR (IDeA-CTR, NIGMS U54GM115677).

Dr. Elwy is funded by a VA Research Career Scientist Award, RCS 23-081, from VA Health Systems Research.

The research team would like to thank our digital assessment partners, including Dr. Andrey Vyshedskiy (Boston Cognitive Assessment), Dr. Alvaro Pascual-Leone (Linus Health), Martina De Lillo (Cambridge Cognition), and Dr. Martin J Sliwinski (M2C2).

Table 1. Demographics

Sample Characteristics (N = 51)	Mean (SD) or N (%)
Age	66.5 (6.3)
Education	15.0 (2.4)
Gender	
female	28 (55%)
male	23 (45%)
Race	
Black or African American	7 (13.7%)
White	44 (86.3%)
Ethnicity	
Hispanic or Latino	1 (2%)
(non-Hispanic or Latino)	50 (98%)
MoCA Total Score	26.7 (2.3)

Table 2. Summary of results of remote online, smartphone, and in-clinic assessments.

	Protocol	Assessment mode	Completions (n/N)	Completion rate (%)	Correlation with MoCA	AUROC MoCA < 26
Boston Cognitive Assessment (BOCA), test #1	1	Online	19/25	76.0	--	--
BOCA test #2 (Day of clinic visit)	1	Online	16/25	64	--	--
BOCA Score (first observed)	1	Online	25/25	--	.671	.776
Paired Associated Learning (PAL) test, CANTAB (total first attempt memory score)	2	Smartphone	16/26	61.5	.53 *ns*	.364
Mobile Monitoring of Cognitive Change (M2C2) App 3x daily	2	Smartphone	15/20	75.0	--	--
M2C2 Symbol Search	--	--	--	--	-.58	.727
M2C2 Grid Memory	--	--	--	--	-.02 *ns*	.50
Digital Clock and Recall (DCR)	1 & 2	In-clinic	36/44	81.8	.60	.781
MoCA	1 & 2	In-clinic or study visit	36	--	NA	NA

Notes: AUROC, Area under the receiver operating characteristic curve; CANTAB, Cambridge Neuropsychological Test Automated Battery; NA, not applicable, the cognitive health consult MoCA was used as the criterion; ns, P > 05. BOCA “first observed” = the first instance of test completion collapsing across administration time points.

Supplemental

Sup. Table 1. Provider feedback interview

Provider	Going well:	Needs improvement:
Clinic A provider 1	**Using the DCR:** "The tool worked very well" "[the patients] understood what they were supposed to do for the most part, I think maybe one person sort of got mixed up at one point, but that was only one." **Recruitment:** "It was also behind the scenes, so I felt like I didn't have to do anything so from my end of things it was perfectly easy."	**Using the DCR:** "There were a couple of times when there were 2 patients listed in there, but the patient's just a number. And I wouldn't know which one to click on." "A tool like [the DCR] that doesn't happen within the confines of the EMR, that's just a barrier to begin with. So, if I have to log in and type in this person, when . . . it's right here in EPIC."
Clinic A provider 2	**Overall:** "I think the protocol worked, people were identified in the schedule with notes that would prompt me about it. [The coordinator] would often prompt me as well to say, "Hey, you have a patient coming on Tuesday."	**Using the DCR:** "It's not as quick for me as doing, say, a mini mental status exam…I find the [DCR] takes longer than that, and then to get the result, I then have to log into the website and get the report from it." "If my medical assistant could do it for me, and I came in and the result was there for me, or, you know, on the tablet, say, or already imported into the record would be great, and that would be that would make me more interested in it."
Clinic B provider 1	**Using the DCR:** "The iPad worked well . . . I wouldn't do anything different." "[the patients] they're very digitally savvy"	**Recruitment:** "The convoluted way of recruiting the patients. It would be good, obviously, if there was somebody in the waiting room, but that can't happen" "The recruitment needs to be more fluid . . . we were running into those problems with allowing you to have access to the patients."

Clinic C provider 1	**Using the DCR:** “I like it a lot. . . I really feel our current screening in the AWV is not good. Having another option that is quick is great” “I really like that the patient is autonomous in completing it . . . I can work on other things”	**Using the DCR:** “Logistical and technical things . . . getting the iPad and hotspot setup, remembering the username and password” “Not getting the results until after the visit. I would like to see the report on the iPad screen.”
Clinic C provider 2	**Using the DCR:** “iPad setup was really straightforward” “I feel like I picked it up very quickly”	**Recruitment:** “It took a while to have access to my EPIC panel and so I ended up having to just send [coordinator] patients”

REFERENCES:

1. Liu Y, Jun H, Becker A, Wallick C, Mattke S. Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population. *The Journal of Prevention of Alzheimer's Disease*. 2023;doi:10.14283/jpad.2023.131
2. Mattke S, Jun H, Chen E, Liu Y, Becker A, Wallick C. Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis. *Alzheimer's Research & Therapy*. 2023;15(1)doi:10.1186/s13195-023-01272-z
3. Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer's Disease. *Nature Reviews Neurology*. 2024/07/01 2024;20(7):426-439. doi:10.1038/s41582-024-00977-5
4. Jack Jr CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's & Dementia*. 2024;20(8):5143-5169.
5. Spencer R, Wendell C, Giggey P, et al. Psychometric Limitations of the Mini-Mental State Examination Among Nondemented Older Adults: An Evaluation of Neurocognitive and Magnetic Resonance Imaging Correlates. Article. *Exp Aging Res*. 2013;39(4):382-397. doi:10.1080/0361073X.2013.808109
6. Mobile and Internet Fact Sheets. Pew Research Center. Accessed June 5, 2025. https://www.pewresearch.org/internet/fact-sheet/mobile/
7. Cubillos C, Rienzo A. Digital Cognitive Assessment Tests for Older Adults: Systematic Literature Review. Review. *JMIR Ment Health*. 2023;10:e47487. doi:10.2196/47487
8. Polk SE, Öhman F, Hassenstab J, et al. A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease. *npj Digital Medicine*. 2025;8(1):1-14.
9. Katz MJ, Wang C, Nester CO, et al. T-MoCA: A valid phone screen for cognitive impairment in diverse community samples. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2021;13(1)doi:10.1002/dad2.12144
10. Gold D, Stockwood J, Boulos K, et al. The Boston cognitive assessment: Psychometric foundations of a self-administered measure of global cognition. *The Clinical Neuropsychologist*. 2022;36(8):2313-2330. doi:10.1080/13854046.2021.1933190
11. Vyshedskiy A, Netson R, Fridberg E, et al. Boston cognitive assessment (BOCA) — a comprehensive self-administered smartphone- and computer-based at-home test for longitudinal tracking of cognitive performance. *BMC Neurol*. 2022;22(1)doi:10.1186/s12883-022-02620-6
12. Padovani A, Caratozzolo S, Galli A, et al. Validation and convergent validity of the Boston cognitive assessment (BOCA) in an Italian population: a comparative study with the Montreal cognitive assessment (MoCA) in Alzheimer's disease spectrum. *Neurol Sci*. 2024:1-8.
13. Barnett JH, Blackwell AD, Sahakian BJ, Robbins TW. The paired associates learning (PAL) test: 30 years of CANTAB translational neuroscience from laboratory to bedside in dementia research. *Translational neuropsychopharmacology*. 2016:449-474.
14. Ashford MT, Aaronson A, Kwang W, et al. Unsupervised Online Paired Associates Learning Task from the Cambridge Neuropsychological Test Automated Battery (CANTAB®) in the Brain

Health Registry. *The Journal of Prevention of Alzheimer's Disease*. 2024/03/01 2024;11(2):514-524. doi:10.14283/jpad.2023.117

15. Reijs BLR, Ramakers I, Köhler S, et al. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. *J Alzheimers Dis*. 2017;60(3):1119-1128. doi:10.3233/jad-160766

16. Soldan A, Pettigrew C, Moghekar A, Albert M. Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior. *J Int Neuropsychol Soc*. Nov 2016;22(10):968-977. doi:10.1017/s1355617716000722

17. Pettigrew C, Soldan A, Brichko R, et al. Computerized paired associate learning performance and imaging biomarkers in older adults without dementia. *Brain Imaging Behav*. Apr 2022;16(2):921-929. doi:10.1007/s11682-021-00583-9

18. Oravecz Z, Harrington KD, Hakun JG, et al. Accounting for retest effects in cognitive testing with the Bayesian double exponential model via intensive measurement burst designs. Original Research. *Front Aging Neurosci*. 2022-September-26 2022;14doi:10.3389/fnagi.2022.897343

19. Thompson LI, De Vito AN, Kunicki ZJ, et al. Psychometric and adherence considerations for high-frequency, smartphone-based cognitive screening protocols in older adults. *J Int Neuropsychol Soc*. 2024;30(8):785-793. doi:10.1017/S1355617724000328

20. Thompson LI, Kunicki ZJ, Emrani S, et al. Remote and in-clinic digital cognitive screening tools outperform the MoCA to distinguish cerebral amyloid status among cognitively healthy older adults. *Alzheimers Dement (Amst)*. 2023;15(4):e12500-e12500. doi:10.1002/dad2.12500

21. Nicosia J, Aschenbrenner AJ, Balota DA, et al. Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer's disease. *Journal of the International Neuropsychological Society : JINS*. 2023;29(5):459-471. doi:10.1017/S135561772200042X

22. Cerino ES, Katz MJ, Wang C, et al. Variability in cognitive performance on mobile devices is sensitive to mild cognitive impairment: Results from the Einstein Aging Study. *Frontiers in Digital Health*. 2021;3:758031.

23. Hammers DB, Fowler NR, Brosch JR, et al. Comparative Performance of the Digital Clock and Recall™ Test, Montreal Cognitive Assessment, and Saint Louis University Mental Status Among Patients in Primary Care. *Alzheimer's & Dementia*. 2023;19:e079034.

24. Jannati A, Toro-Serey C, Gomes-Osman J, et al. Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia. *Alzheimer's Research & Therapy*. 2024;16(1)doi:10.1186/s13195-023-01367-7

25. Hammers DB, Schulman D, Fowler NR, et al. Performance of Older Adults on the Digital Clock and Recall Test Compared to the Montreal Cognitive Assessment in Primary Care Settings: Hammers et al. *J Gen Intern Med*. 2025:1-9.

26. Nasreddine ZS, Phillips NA, Bã©Dirian VR, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. *J Am Geriatr Soc*. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x

27. Young SR, Dworak EM, Byrne GJ, et al. Remote Self-Administration of Cognitive Screeners for Older Adults Prior to a Primary Care Visit: Pilot Cross-Sectional Study of the Reliability and Usability of the MyCog Mobile Screening App. Original Paper. *JMIR Form Res*. 2024;8:e54299. doi:10.2196/54299

28. Ratcliffe LN, Taylor M, Brittany R, R. SJ, W. LD, and Hewitt KC. Classification statistics of the Montreal Cognitive Assessment (MoCA): Are we interpreting the MoCA correctly? *The Clinical Neuropsychologist*. 2023/04/03 2023;37(3):562-576. doi:10.1080/13854046.2022.2086487
29. Stimmel MB, Orkaby AR, Ayers E, Verghese J, Nsubayi CK, Weiss EF. Is the Montreal cognitive assessment culturally valid in a diverse geriatric primary care setting? Lessons from the Bronx. *J Am Geriatr Soc*. 2024;72(3):850-857. doi:https://doi.org/10.1111/jgs.18705
30. Sideman AB, Chalmer R, Ayers E, et al. Lessons from Detecting Cognitive Impairment Including Dementia (DetectCID) in Primary Care. *J Alzheimers Dis*. 2022;Preprint:1-11. doi:10.3233/JAD-215106